Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP14 | P31944 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | CASP4 | P49662 | 1/20 | 0.59 |
| ▸ | CASP5 | P51878 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | CASP9 | P55211 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.59 |
| ▸ | CASP12 | Q6UXS9 | 1/20 | 0.59 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.52 |
| ▸ | TUBB | P07437 | 1/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12084591 | 0.86 | EGFR (0.67) | EGFRPDGFRBKDRCASP1CASP14 | |
| SCHEMBL3114823 | 0.81 | EGFR (0.64) | EGFRPDGFRBKDRCASP1CASP14 | |
| SCHEMBL3118902 | 0.81 | EGFR (0.75) | EGFRPDGFRBKDRCASP1CASP14 | |
| Verubulin SCHEMBL29379614 | 0.81 | KDR (1.00) | EGFRPDGFRBKDRCASP1CASP14 | |
| Verubulin SCHEMBL2232326 | 0.81 | KDR (1.00) | EGFRPDGFRBKDRCASP1CASP14 | |
| SCHEMBL3110866 | 0.81 | EGFR (0.62) | EGFRPDGFRBKDRCASP1CASP14 | |
| Verubulin SCHEMBL2395194 | 0.80 | KDR (0.97) | EGFRPDGFRBKDRCASP1CASP14 | |
| Verubulin SCHEMBL29505369 | 0.80 | KDR (0.97) | EGFRPDGFRBKDRCASP1CASP14 | |
| SCHEMBL2257339 | 0.80 | EGFR (1.00) | EGFRPDGFRBKDRCASP1CASP14 | |
| SCHEMBL3113583 | 0.80 | EGFR (0.73) | EGFRPDGFRBKDRCASP1CASP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102088854-A | Pharmaceutical compounds as cytotoxic agents and methods of use thereof | MYRIAD PHARMACEUTICALS INC | 2011-06-08 | — | — | CN | claimed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110224240-A1 | METHODS OF TREATING CANCER AND RELATED DISEASES | MYREXIS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224240-A1 | METHODS OF TREATING CANCER AND RELATED DISEASES | MYREXIS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224240-A1 | METHODS OF TREATING CANCER AND RELATED DISEASES | MYREXIS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110200619-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF | MYREXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110200619-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF | MYREXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110200619-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF | MYREXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| CN-102088854-A | Pharmaceutical compounds as cytotoxic agents and methods of use thereof | MYRIAD PHARMACEUTICALS INC | 2011-06-08 | — | — | CN | disclosed |
| EP-2309856-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND THE USE THEREOF | Myrexis, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010006115-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | EGFR 3147/4885PDGFRB 2783/4885KDR 3722/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2648/4885PDGFRB 2627/4885KDR 3809/4885 |
| US-20110224240-A1 | METHODS OF TREATING CANCER AND RELATED DISEASES | VHL, GLS2, SLC19A1 | EGFR 762/4885PDGFRB 2165/4885KDR 1732/4885 |
| US-20110200619-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF | TP53, NFATC1, BAD | EGFR 1214/4885PDGFRB 1897/4885KDR 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.